Publications by authors named "S P Gaine"
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant, multisystem disorder that manifests with a spectrum of disease including cardiopulmonary complications. HHT is characterised by aberrant signalling via the transforming growth factor β (TGFβ) pathway, with loss of vascular integrity, angiogenesis and vascular dysplasia. The disease has an estimated prevalence of 1 in 5000 persons and the penetrance increases with increasing age.
View Article and Find Full Text PDFExercise training is recommended for pulmonary hypertension (PH). Post hoc analysis of the PH and Home-Based (PHAHB) trial stratified patients into two groups based on median diffusing capacity of the lungs for carbon monoxide (DLCO). Patients with higher DLCO had a greater improvement in physical activity performance in response to exercise training, compared to those with lower DLCO.
View Article and Find Full Text PDFArticle Synopsis
- The study aims to evaluate the performance and safety of subcutaneous-implantable cardioverter defibrillator (S-ICD) technology in athletes compared to nonathletes, focusing on device-related complications and shock occurrences.
- Athletes made up 10.2% of the 1493 patients studied and showed higher incidences of certain heart conditions, with a tendency to experience appropriate shocks more frequently during exercise, although this was not statistically significant after adjusting for other factors.
- Overall, S-ICDs appear to be a safe option for athletes, as there was no significant difference in overall complications or inappropriate shocks between the two groups, though athletes had a higher risk of myopotential oversensing and lead infections shortly after implant.
Background: Mortality risk assessment informs clinical management of pulmonary arterial hypertension (PAH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 is a simplified risk calculator discriminating 1-year mortality risk.
Methods: This post-hoc analysis of the phase 3 GRIPHON study assessed changes in REVEAL Lite 2 risk score with selexipag versus placebo and whether changes were prognostic or predictive of time to first morbidity/mortality (M/M) event.